The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma.
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Merck; Merck; Merck; Merck; Tesaro; Tesaro; Tesaro; Tesaro
Travel, Accommodations, Expenses - Agios; Agios; Agios; Agios; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
Srivatsan Raghavan
No Relationships to Disclose
 
Yvonne Y. Li
No Relationships to Disclose
 
Liam Spurr
Employment - Amgen; Amgen; Amgen; Amgen; Genzyme (I); Genzyme (I); Genzyme (I); Genzyme (I)
 
Qibiao Wu
No Relationships to Disclose
 
Lei Shi
No Relationships to Disclose
 
Lauren K. Brais
No Relationships to Disclose
 
Zunelly Odhiambo
No Relationships to Disclose
 
Lipika Goyal
Consulting or Advisory Role - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Anuj K. Patel
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai
Research Funding - Analysis Group (Inst); Analysis Group (Inst); Analysis Group (Inst); Analysis Group (Inst)
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai
 
Atul B. Shinagare
Honoraria - Arog; Arog; Arog; Arog
Consulting or Advisory Role - Arog; Arog; Arog; Arog
 
Thomas E. Clancy
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Almac Diagnostics; Almac Diagnostics; Almac Diagnostics; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Cybrexa Therapeutics; Cybrexa Therapeutics; Cybrexa Therapeutics; Cybrexa Therapeutics; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Fusion Pharmaceuticals; Fusion Pharmaceuticals; Fusion Pharmaceuticals; Fusion Pharmaceuticals; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Sierra Oncology; Sierra Oncology; Sierra Oncology; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Aileron Therapeutics (Inst); Aileron Therapeutics (Inst); Aileron Therapeutics (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); CanBas (Inst); CanBas (Inst); CanBas (Inst); CanBas (Inst); Cellceutix (Inst); Cellceutix (Inst); Cellceutix (Inst); Cellceutix (Inst); Covidien (Inst); Covidien (Inst); Covidien (Inst); Covidien (Inst); Curis (Inst); Curis (Inst); Curis (Inst); Curis (Inst); Cyclacel (Inst); Cyclacel (Inst); Cyclacel (Inst); Cyclacel (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Immune Design (Inst); Immune Design (Inst); Immune Design (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); PharmaMar (Inst); PharmaMar (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Sierra Oncology (Inst); Sierra Oncology (Inst); Sierra Oncology (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tensha Therapeutics (Inst); Tensha Therapeutics (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Vertex (Inst); Vertex (Inst); Vertex (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Lilly; Lilly; Lilly; Lilly; Pfizer; Pfizer; Pfizer; Pfizer; Sierra Oncology; Sierra Oncology; Sierra Oncology; Sierra Oncology
 
Ethan Cerami
Stock and Other Ownership Interests - Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines
Honoraria - Merck; Merck; Merck; Merck
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck
 
William R. Sellers
Leadership - Bluebird Bio; Bluebird Bio; Bluebird Bio; Bluebird Bio; Civetta Therapeutics; Civetta Therapeutics; Civetta Therapeutics; Civetta Therapeutics; Novartis; Novartis; Novartis; Novartis; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics
Stock and Other Ownership Interests - Civetta Therapeutics; Civetta Therapeutics; Civetta Therapeutics; Civetta Therapeutics; Ideaya Biosciences; Ideaya Biosciences; Ideaya Biosciences; Ideaya Biosciences; Novartis; Novartis; Novartis; Novartis; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Dynamo Therapeutics; Dynamo Therapeutics; Dynamo Therapeutics; Dynamo Therapeutics; Epidarex Capital; Epidarex Capital; Epidarex Capital; Epidarex Capital; IDEAYA Biosciences; IDEAYA Biosciences; IDEAYA Biosciences; IDEAYA Biosciences; Ipsen; Ipsen; Ipsen; Ipsen; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; SERVIER; SERVIER; SERVIER; SERVIER; Syndax; Syndax; Syndax; Syndax; Vida Ventures; Vida Ventures; Vida Ventures; Vida Ventures
Research Funding - Deerfield Management; Deerfield Management; Deerfield Management; Deerfield Management
Patents, Royalties, Other Intellectual Property - EGFR mutations patent - Royalties; EGFR mutations patent - Royalties; EGFR mutations patent - Royalties; EGFR mutations patent - Royalties
Travel, Accommodations, Expenses - Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Bluebird Bio; Bluebird Bio; Bluebird Bio; Bluebird Bio; IDEAYA Biosciences; IDEAYA Biosciences; IDEAYA Biosciences; IDEAYA Biosciences; Merck; Merck; Merck; Merck; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; SERVIER; SERVIER; SERVIER; SERVIER
 
William C. Hahn
Stock and Other Ownership Interests - Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines
Consulting or Advisory Role - AJU IB; AJU IB; AJU IB; AJU IB; KSQ Therapeutics; KSQ Therapeutics; KSQ Therapeutics; KSQ Therapeutics; MPM Capital; MPM Capital; MPM Capital; MPM Capital; Novartis; Novartis; Novartis; Novartis; Thermo Fisher Scientific; Thermo Fisher Scientific; Thermo Fisher Scientific; Thermo Fisher Scientific
Research Funding - Novartis; Novartis; Novartis; Novartis
 
Andrew D. Cherniack
Employment - LabCorp (I); LabCorp (I); LabCorp (I); LabCorp (I)
Stock and Other Ownership Interests - Merck; Merck; Merck; Merck
Research Funding - Bayer; Bayer; Bayer; Bayer
 
Nabeel Bardeesy
No Relationships to Disclose
 
Matthew Meyerson
Stock and Other Ownership Interests - OrigiMed; OrigiMed; OrigiMed; OrigiMed
Consulting or Advisory Role - OrigiMed; OrigiMed; OrigiMed; OrigiMed
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Patent on EGFR mutations for lung cancer diagnosis; Patent on EGFR mutations for lung cancer diagnosis; Patent on EGFR mutations for lung cancer diagnosis; Patent on EGFR mutations for lung cancer diagnosis
 
Brian M. Wolpin
Honoraria - Celgene; Celgene; Celgene; Celgene; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; BioLineRx; BioLineRx; BioLineRx; Celgene; Celgene; Celgene; Celgene; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Genentech; Genentech; Genentech; Genentech; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL
Research Funding - Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly